1-6 of 247 Activities
Traditional diagnosis and treatment of Alzheimer’s disease (AD) has relied heavily on the clinical expertise of healthcare professionals (HCPs) and patient-reported symptoms. However, recently revised diagnostic criteria incorporate biomarkers—such as amyloid and tau pathology—and advanced imaging modalities, including amyloid, tau, and fluorodeoxyglucose (FDG) positron emission tomography (PET) scans, to enhance early detection and determine eligibility for targeted therapies. Imaging clinicians in nuclear medicine, as part of the multidisciplinary team, would benefit from education on best practices for the use, interpretation, and reporting of PET imaging to support timely and accurate diagnosis and guide treatment decisions.
In this Efficient CME livestream symposium, expert faculty will examine and share best practices for interpreting and reporting PET imaging in early AD and provide opportunities to test your skills using a highly interactive format to help improve real-world practices.
In this CME Outfitters livestream symposium, leading experts will explore:
✅ Early, guideline-based diagnosis to improve patient outcomes
✅ The latest efficacy and safety data on current and emerging therapies, including oral treatments
✅ Individualized care strategies that consider patient needs, comorbidities, and barriers to adherence
Stay ahead of the curve with cutting-edge insights to enhance patient care and optimize long-term management of acromegaly.
In this CME Outfitters live webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.
In this CME Outfitters recorded symposium, faculty will examine the role of pro-inflammatory cytokines in the pathogenesis of IBD, discern differences in IL-23 binding among IL-23p19–targeted therapies, assess the safety and efficacy of IL-23p19–targeted therapies for the treatment of IBD, and explore when to incorporate IL-23p19–targeted therapies into the management of patients with IBD.
Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.
Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.
Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.
Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.
In this CME Outfitters chapter meeting, expert faculty will discuss important strategies for identifying how to best overcome delays in insulin initiation as well as how to differentiate current and emerging basal insulin therapies and their impact on therapeutic inertia.
In this CME Outfitters recorded symposium, expert faculty will guide learners on identifying signs and symptoms of PBC, MASH, and MASLD, implementing evidence-based strategies for early and accurate diagnosis, implementing best practices for treatment, and applying multidisciplinary disease management to the care of patients.
